TCEB3C Antibody

What is TCEB3C and why is it significant in cancer research?

TCEB3C encodes Elongin A3, which has been identified as a putative tumor suppressor gene located on chromosome 18. Its significance in cancer research stems from observations in small intestinal neuroendocrine tumors (SI-NETs), where frequent loss of one copy of chromosome 18 occurs in both primary tumors and metastases. Studies show that a large majority (33/43) of SI-NETs demonstrate very low to undetectable Elongin A3 expression, with approximately 89% (40/45) of tumors displaying only one gene copy of TCEB3C . Furthermore, overexpression of TCEB3C in SI-NET cell lines results in approximately 50% decrease in clonogenic survival, supporting its role as a tumor suppressor gene . This makes TCEB3C a valuable target for researchers investigating mechanisms of tumor suppression and potential therapeutic interventions in neuroendocrine tumors.

How does TCEB3C antibody detection compare with other methods of evaluating TCEB3C expression?

TCEB3C antibody detection through immunohistochemistry provides distinct advantages over other detection methods, particularly when investigating protein expression patterns in tissue samples. While PCR-based methods and RT-PCR can quantify gene copy number and mRNA expression respectively, antibody-based detection allows visualization of protein localization and expression levels in different cell types within heterogeneous tissues. In research with SI-NETs, rabbit polyclonal anti-TCEB3C antibody has been successfully used to detect Elongin A3 in chromogranin A-positive cells of the small intestine, revealing important spatial information such as the observation that some tumors with insular growth patterns show negative staining in the majority of insular cells but strong positive staining in cells surrounding the islets . This spatial information cannot be obtained through PCR or RT-PCR. For validation purposes, peptide-blocking experiments have confirmed antibody specificity, demonstrating that staining can be successfully blocked by immunizing peptide . When comprehensive analysis is needed, complementary approaches combining antibody detection with quantitative PCR for gene copy number assessment and real-time quantitative RT-PCR for mRNA expression provide the most complete picture of TCEB3C status.

What are the key controls needed when using TCEB3C antibody in experimental procedures?

When employing TCEB3C antibody in experimental procedures, several critical controls are essential to ensure reliable and interpretable results. First, peptide competition assays should be performed to validate antibody specificity, as demonstrated in studies where rabbit anti-TCEB3C antibody staining was successfully blocked by the immunizing peptide . Second, positive tissue controls are crucial - normal small intestinal tissue showing Elongin A3 expression in chromogranin A-positive cells provides an appropriate positive control for SI-NET research . Third, negative controls should include tissues or cell lines known to have TCEB3C gene deletion or very low expression. Fourth, when studying epigenetic regulation, appropriate controls for treatment efficacy must be included - for instance, when using DNA hypomethylating agents like 5-aza-2'-deoxycytidine or histone methyltransferase inhibitors like DZNep, verification of their activity using known epigenetically regulated genes is essential . Fifth, antibody concentration optimization through titration experiments is necessary to determine optimal signal-to-noise ratios. Finally, when analyzing gene copy number in parallel, inclusion of samples with known copy numbers from previous LOH analyses serves as an important control for quantitative PCR assay validation . Implementing these controls systematically enhances result reliability and facilitates accurate interpretation of TCEB3C antibody-based experiments.

What is the optimal protocol for immunohistochemical detection of TCEB3C/Elongin A3 in tumor tissues?

The optimal protocol for immunohistochemical detection of TCEB3C/Elongin A3 in tumor tissues requires careful attention to several critical parameters. Based on successful research applications, tissues should first undergo standard fixation in formalin and embedding in paraffin. For antigen retrieval, heat-induced epitope retrieval in citrate buffer (pH 6.0) is recommended to unmask antigens that may have been cross-linked during fixation. When selecting primary antibodies, rabbit polyclonal anti-TCEB3C antibodies have demonstrated excellent specificity in detecting Elongin A3, particularly when validated through peptide blocking experiments . The optimal antibody dilution should be determined empirically for each lot through titration experiments, typically in the range of 1:100 to 1:500. For detection systems, polymer-based detection methods provide superior sensitivity and reduced background compared to avidin-biotin systems. Counterstaining with hematoxylin provides excellent nuclear contrast without obscuring cytoplasmic Elongin A3 staining. The inclusion of both positive controls (normal small intestinal tissue with chromogranin A-positive cells) and negative controls (antibody diluent only, plus peptide competition controls) is essential for result validation . For dual staining applications, when examining Elongin A3 in relation to other markers such as chromogranin A, sequential staining protocols with appropriate blocking steps between primary antibodies are recommended to prevent cross-reactivity.

How should researchers design experiments to investigate epigenetic regulation of TCEB3C expression?

Designing robust experiments to investigate epigenetic regulation of TCEB3C expression requires a comprehensive, multi-layered approach. First, researchers should establish baseline TCEB3C expression in their model systems using quantitative RT-PCR for mRNA and western blotting or immunohistochemistry with anti-TCEB3C antibodies for protein detection. To investigate DNA methylation, treatment with DNA hypomethylating agents such as 5-aza-2'-deoxycytidine at various concentrations (typically 1-5 μM) and timepoints should be conducted, followed by TCEB3C expression analysis . For histone modification analysis, researchers should employ histone methyltransferase inhibitors such as 3-deazaneplanocin A (DZNep), which has been shown to strongly induce TCEB3C mRNA expression (up to 80-fold in some cell lines) . Additionally, targeted approaches using siRNA to specific epigenetic regulators (e.g., DNMT1) can provide mechanistic insights into the specific factors controlling TCEB3C expression . For comprehensive epigenetic profiling, quantitative CpG methylation analysis by pyrosequencing of the TCEB3C promoter should be performed alongside chromatin immunoprecipitation (ChIP) assays to assess histone modifications at the TCEB3C locus. Importantly, researchers must include cell type-specific controls, as epigenetic repression of TCEB3C has been shown to be tumor cell type-specific, with varying responses to epigenetic modifiers across different cell lines . Finally, correlation analyses between epigenetic modifications and TCEB3C expression levels in patient-derived samples can provide clinically relevant insights into the epigenetic regulation mechanisms operating in vivo.

What are the key considerations when analyzing TCEB3C copy number in conjunction with antibody-based protein detection?

When analyzing TCEB3C copy number in conjunction with antibody-based protein detection, researchers must address several critical considerations to ensure accurate data interpretation. First, sample selection and preparation are paramount - DNA and protein should ideally be extracted from the same tumor regions to enable direct correlations between gene copy number and protein expression. For gene copy number analysis, duplex quantitative real-time PCR with appropriate reference genes (such as RNaseP or TERT) should be employed, with careful attention to primer design to avoid amplification of pseudogenes or related family members . Multiple replicates (minimum of four) should be analyzed using 20 ng DNA per well, with calibrators such as placenta or blood DNA from healthy donors. For validation, known control samples with previously determined copy numbers should be included . In parallel, protein expression analysis using anti-TCEB3C antibodies should be performed through western blotting (for quantitative analysis) or immunohistochemistry (for spatial expression patterns). When interpreting results, researchers must consider that the relationship between gene copy number and protein expression is not always linear - in SI-NETs, while 89% of tumors display one TCEB3C gene copy, there is variability in protein expression patterns, with some single-copy tumors showing detectable protein expression . This suggests that mechanisms beyond gene dosage, such as epigenetic regulation, influence protein expression. Finally, statistical analysis should include correlation coefficients between copy number status and protein expression levels, accounting for potential confounding variables such as tumor grade, location, and treatment history.

How can TCEB3C antibody be utilized in developing novel T-cell engager therapies for tumors with aberrant TCEB3C expression?

TCEB3C antibody could be strategically incorporated into novel T-cell engager (TCE) therapies targeting tumors with aberrant TCEB3C expression through several innovative approaches. Given that a large majority of SI-NETs show low or undetectable Elongin A3 expression despite retaining one TCEB3C gene copy , approaches could focus on tumors where epigenetic derepression has restored TCEB3C expression. One promising strategy involves developing trispecific antibodies that co-target TCEB3C alongside another tumor marker (such as chromogranin A) and CD3 on T cells, similar to approaches that have shown efficacy with Ly6E and B7-H4 co-targeting . The relative placement of binding domains would be crucial, with the higher-affinity domain positioned optimally for maximal efficacy, as demonstrated in other trispecific TCE models . To address potential on-target toxicity in normal tissues with TCEB3C expression, researchers could implement conditional binding mechanisms, such as pH-dependent binding that activates only in the tumor microenvironment . For development and testing, researchers would need to generate knobs-into-holes antibody constructs with anti-TCEB3C components of varied affinities, as the balance between anti-tumor activity and on-target toxicity is influenced by binding affinity . Validation would require in vitro killing assays using cell lines with differential TCEB3C expression levels followed by xenograft models to assess in vivo efficacy and tolerability. This approach leverages the growing field of multispecific antibodies while targeting the unique biology of TCEB3C in neuroendocrine tumors.

What techniques can be employed to analyze contradictory data between TCEB3C antibody staining patterns and mRNA expression levels?

Resolving contradictions between TCEB3C antibody staining patterns and mRNA expression levels requires a systematic multi-technique approach to identify the source of discrepancies. First, researchers should validate antibody specificity through multiple methods, including peptide competition assays, western blotting against recombinant Elongin A3, and testing in TCEB3C knockout models to eliminate false positive staining . For mRNA analysis verification, researchers should employ multiple primer sets targeting different exons of TCEB3C to account for potential splice variants or partial transcripts that might explain discordant results. Digital droplet PCR provides higher sensitivity than traditional qRT-PCR and can detect low-abundance transcripts that might be missed by conventional methods. RNA-sequencing can further identify novel splice variants or antisense transcripts that might interfere with traditional detection methods. To address potential post-transcriptional regulation, researchers should investigate microRNA-mediated suppression of TCEB3C translation through microRNA profiling and luciferase reporter assays with the TCEB3C 3'UTR. Protein stability assessments using proteasome inhibitors can determine if Elongin A3 undergoes rapid degradation despite normal transcription. For spatial discrepancies, laser capture microdissection of specific cellular regions followed by parallel mRNA and protein analysis can reveal microenvironmental influences on expression. Finally, single-cell RNA-seq paired with multiplexed immunofluorescence can provide resolution at the single-cell level, potentially revealing subpopulations with distinct expression patterns that might be obscured in bulk analysis . This comprehensive approach enables researchers to distinguish biological phenomena from technical artifacts.

How can TCEB3C antibody be integrated into high-throughput screening platforms for epigenetic modulators?

Integration of TCEB3C antibody into high-throughput screening (HTS) platforms for epigenetic modulators presents an innovative approach for identifying compounds that restore tumor suppressor function. Researchers should begin by developing cell-based assays using SI-NET cell lines with epigenetically silenced TCEB3C, such as CNDT2.5, which has demonstrated responsiveness to epigenetic modifiers in previous studies . For primary screening, an automated immunocytochemistry platform utilizing fluorescently-labeled anti-TCEB3C antibodies can be established in 384-well format, allowing quantitative image analysis of nuclear and cytoplasmic Elongin A3 expression following compound treatment. This system can be coupled with high-content imaging to simultaneously assess cellular phenotypes associated with TCEB3C re-expression, such as proliferation inhibition. For validation, an orthogonal assay employing a TCEB3C promoter-luciferase reporter system provides a rapid secondary screen to confirm hits that activate transcription. To enhance specificity, counterscreening against cell lines where TCEB3C is not epigenetically regulated (such as sHPT-1 or HEK293T) helps eliminate compounds with non-specific effects . The most promising compounds can be further evaluated through RT-PCR and western blotting to confirm TCEB3C re-expression, followed by functional assays such as colony formation to assess tumor suppressive effects . Additionally, incorporation of chromatin immunoprecipitation coupled with quantitative PCR can determine whether hit compounds specifically affect histone modifications at the TCEB3C locus. This integrated approach enables systematic identification of epigenetic modulators that specifically reactivate TCEB3C expression, potentially leading to novel therapeutic strategies for SI-NETs and other cancers with epigenetically silenced tumor suppressors.

What are the common challenges in achieving optimal TCEB3C antibody staining in formalin-fixed, paraffin-embedded tissues?

Researchers frequently encounter several challenges when optimizing TCEB3C antibody staining in formalin-fixed, paraffin-embedded (FFPE) tissues. First, overfixation in formalin (beyond 24 hours) can create excessive protein cross-linking that masks TCEB3C epitopes, necessitating aggressive antigen retrieval methods that may damage tissue morphology. To address this, researchers should standardize fixation times (12-24 hours optimal) and experiment with different antigen retrieval methods, including heat-induced epitope retrieval with citrate buffer (pH 6.0) at varying temperatures and durations, or enzymatic retrieval with proteinase K for difficult samples. Second, low endogenous expression of Elongin A3 in many tissues requires signal amplification techniques - researchers should consider tyramide signal amplification systems which can enhance sensitivity 10-100 fold without increasing background. Third, high background staining, particularly in tissues with high lipid content, can be mitigated through extended blocking steps (3% BSA with 0.3% Triton X-100) and inclusion of avidin/biotin blocking steps when using biotin-based detection systems. Fourth, inconsistent staining may result from TCEB3C antibody batch variation - researchers should perform lot-to-lot validation using known positive controls (such as chromogranin A-positive cells in normal small intestine) and consider preparing large batches of working dilution stored as single-use aliquots. Fifth, false negatives due to epitope masking by protein-protein interactions can be addressed by including detergent pre-treatment steps or brief protease digestion. Lastly, when quantifying staining patterns, researchers should implement digital image analysis with appropriate thresholding to objectively classify cells as negative, weakly positive, or strongly positive, particularly when evaluating heterogeneous staining patterns as observed in insular growth patterns of some SI-NETs .

How can researchers optimize western blot protocols for detecting TCEB3C in samples with low expression levels?

Optimizing western blot protocols for detecting TCEB3C in samples with low expression levels requires systematic refinement of each step in the procedure. First, researchers should maximize protein extraction efficiency by using RIPA buffer supplemented with protease inhibitors, coupled with mechanical disruption techniques such as sonication or needle passage for complete lysis. For tissue samples, addition of 0.1% SDS can improve solubilization of membrane-associated proteins. Second, protein concentration should be increased to 50-75 μg per lane (versus standard 20-30 μg) to enhance detection sensitivity. Third, extended transfer times (overnight at 30V in cold room conditions) improve transfer efficiency of proteins to PVDF membranes, which offer superior protein binding capacity compared to nitrocellulose for low-abundance proteins. Fourth, blocking conditions should be optimized - 5% non-fat dry milk in TBST may cause lower sensitivity than 3% BSA for phospho-epitopes. Fifth, primary antibody incubation should be extended to overnight at 4°C with gentle rocking, using optimized antibody concentration determined through systematic titration. Sixth, enhanced chemiluminescence (ECL) systems with femtogram-level sensitivity should be employed, with consideration of newer technologies such as WesternBright Quantum which can detect proteins at the attomole range. Seventh, signal amplification can be achieved using biotin-streptavidin systems or polymer-based secondary antibodies. Eighth, digital image acquisition with cooled CCD cameras allows extended exposure times without background accumulation, unlike film-based detection. Finally, researchers should consider sample enrichment techniques prior to western blotting, such as immunoprecipitation of TCEB3C/Elongin A3 to concentrate the target protein, a strategy particularly useful when measuring TCEB3C in cell lines like CNDT2.5 that show very low baseline expression but respond to epigenetic modifiers with increased expression .

What strategies can overcome cross-reactivity issues when using TCEB3C antibody in multiplexed immunofluorescence studies?

Addressing cross-reactivity issues in multiplexed immunofluorescence studies involving TCEB3C antibody requires comprehensive technical strategies. First, researchers should conduct thorough antibody validation using single-staining controls alongside peptide competition assays to confirm specificity before multiplexing . When selecting additional antibodies for multiplexing, prioritize those raised in different host species than the TCEB3C antibody to enable species-specific secondary antibodies. For instances where antibodies from the same species are unavoidable, implement sequential staining protocols with direct fluorophore conjugation of the primary antibodies or use zenon labeling technology to pre-label primary antibodies with different fluorophores. To minimize spectral overlap between fluorophores, select fluorophores with minimal spectral overlap and implement linear unmixing algorithms during image acquisition. Cross-adsorbed secondary antibodies specifically designed to minimize cross-species reactivity are essential when using multiple primary antibodies. Researchers should also employ tyramide signal amplification (TSA) systems, which allow antibody stripping between staining rounds while preserving the amplified signal from previous rounds, enabling sequential multiplexing with same-species antibodies. Optimized blocking protocols using both serum matching the species of secondary antibodies and commercial blocking reagents designed for multiplexed immunofluorescence can significantly reduce non-specific binding. For tissue autofluorescence, which is particularly problematic in FFPE samples, pre-treatment with Sudan Black B (0.1% in 70% ethanol) or commercial autofluorescence quenchers can substantially improve signal-to-noise ratio. Finally, implementing automated multispectral imaging systems with computational analysis allows precise separation of spectrally overlapping signals and quantitative analysis of co-localization patterns, particularly valuable when investigating relationships between TCEB3C/Elongin A3 and other markers in heterogeneous tumor samples.

How should heterogeneous TCEB3C staining patterns in tumors be interpreted in relation to tumor biology?

Heterogeneous TCEB3C staining patterns in tumors provide crucial insights into tumor biology that require sophisticated interpretation. First, researchers should recognize that the observed insular growth pattern in SI-NETs, where tumor islets show negative staining while cells surrounding the islets display strong positive staining, suggests distinct biological subpopulations with potentially different functions . This pattern may indicate that Elongin A3 expression influences cellular location and intercellular communication within the tumor microenvironment. Second, heterogeneity should be quantified using digital pathology tools that can measure not only the percentage of positive cells but also staining intensity and spatial relationships, yielding metrics such as "immune exclusion" or "invasive margin" patterns. Third, correlation analyses between TCEB3C expression patterns and clinicopathological features are essential - researchers should examine whether heterogeneous expression correlates with tumor grade, stage, or patient outcomes. Published data indicate no significant difference in staining patterns between Grade 1 and Grade 2 SI-NETs, suggesting this heterogeneity transcends traditional grading systems . Fourth, longitudinal analysis of matched primary tumors and metastases can reveal evolution of TCEB3C expression - some patients show positive staining in primary tumors but negative staining in lymph node metastases, while others display the opposite pattern in liver metastases, indicating potential selection pressures during metastatic progression . Fifth, co-expression analysis with other markers (chromogranin A, Ki-67, EMT markers) through multiplexed immunohistochemistry can reveal functional relationships between TCEB3C expression and other biological processes. Finally, single-cell RNA sequencing of regions with different staining patterns can identify transcriptional programs associated with TCEB3C expression or silencing, potentially revealing mechanisms underlying this heterogeneity and its biological significance.

What are the implications of discordant findings between TCEB3C gene copy number and protein expression?

Discordant findings between TCEB3C gene copy number and protein expression observed in SI-NETs reveal complex regulatory mechanisms with significant implications for cancer biology and therapeutic approaches. First, the observation that 89% of SI-NETs display one TCEB3C gene copy (consistent with chromosome 18 loss), yet protein expression patterns are variable, strongly suggests that post-genomic regulatory mechanisms play a dominant role in controlling Elongin A3 levels . This highlights the importance of epigenetic regulation in tumorigenesis beyond simple genetic alterations. Second, researchers should consider that haploinsufficiency of TCEB3C may be insufficient to completely abolish protein expression, but rather creates a vulnerability where additional epigenetic silencing can completely eliminate tumor suppressor function. Third, discordance patterns may identify distinct molecular subtypes of SI-NETs with different biological behaviors - patients whose tumors retain protein expression despite gene copy loss might represent a distinct prognostic category. Fourth, these findings suggest potential therapeutic vulnerabilities, as tumors with intact but epigenetically silenced TCEB3C may be responsive to epigenetic modifiers that can restore expression, as demonstrated in vitro with 5-aza-2'-deoxycytidine and DZNep . Fifth, from a diagnostic perspective, complementary testing for both gene copy number and protein expression provides more complete information than either alone. Sixth, the tissue-specific nature of epigenetic silencing observed (where identical treatments induce TCEB3C expression in SI-NET cells but not in parathyroid or HEK293T cells) suggests unique epigenetic vulnerabilities that could be exploited for targeted therapy approaches . Finally, these discordant findings underscore the need for multi-omic approaches in cancer research that integrate genomic, epigenomic, transcriptomic, and proteomic data to fully understand the complex regulatory networks governing tumor suppressor function.

How can TCEB3C antibody data be integrated with Rep-Seq datasets to advance immunotherapy research?

Integrating TCEB3C antibody data with Repertoire Sequencing (Rep-Seq) datasets presents a sophisticated approach to advancing immunotherapy research, particularly for neuroendocrine tumors. First, researchers can utilize platforms like RAPID that automatically annotate antibody clones and allow easy querying of antibodies or repertoires to identify naturally occurring antibodies against Elongin A3 in patient samples, potentially revealing endogenous immune responses against this tumor suppressor. Second, spatial transcriptomics combined with TCEB3C immunohistochemistry can map the relationship between immune infiltrates and Elongin A3 expression patterns, particularly relevant given the heterogeneous staining observed in insular growth patterns of SI-NETs . Third, Rep-Seq analysis of tumor-infiltrating lymphocytes from regions with different TCEB3C expression levels can reveal whether specific T-cell or B-cell clonotypes are enriched in areas with restored TCEB3C expression following epigenetic therapy, indicating potential immunomodulatory effects of TCEB3C re-expression. Fourth, by analyzing public Rep-seq datasets representing different tissues, health conditions, and ages , researchers can identify tissue-specific immune signatures that correlate with TCEB3C expression levels, potentially explaining differential responses to immunotherapy. Fifth, integration of Rep-Seq data with TCEB3C expression patterns could inform design of more effective T-cell engager therapies by identifying optimal T-cell epitopes and antibody formats, building on approaches used for dual-targeting trispecific T-cell engagers . Finally, computational integration of antibody repertoire data with TCEB3C expression data across multiple cancer types could reveal previously unrecognized patterns in immune surveillance of TCEB3C-expressing versus TCEB3C-silenced tumors, potentially identifying patient subgroups most likely to benefit from combination approaches using epigenetic modifiers to restore TCEB3C expression followed by immunotherapy to eliminate those cells recognized by the immune system.